Coronary Clinical Study Overview
(As of March 2020)

Excellent Safety Outcomes
In Published Core Lab Adjudicated Studies (DISRUPT CAD I & II)

- 0% Major Dissections
- 0% Perforations
- 0% Slow/No Reflow
- 6.7% 30-day MACE
  (12/179; 10 Non–Q-wave MI)

Patient Outcomes Published-to-Date: 180
Patients in Ongoing Studies: 456
Patients in Approved Studies to be Enrolled: 1130

DISRUPT CAD I (EU)
DISRUPT CAD II (EU)
DISRUPT CAD III (US, UK, FR, DE)
DISRUPT CAD IV (JP)
Left Main Study (UK)
IVL & DCB Study (DE)
IVL in Bifurcations (DE)
French Registry (FR)
Spanish Registry (ES)
IVL vs POBA (NZ)

Company Sponsored
Investigator-Initiated
- Study Published
- Study in Progress
- Study Planned
Coronary IVL Bibliography as of Q1 2020

Multi-Center Studies:
   [Link Here]

Single Center, Case Reports and Other:
24. Kwok, OH and Tse, HF. Ventricular Capture During Shockwave Intravascular Lithotripsy. JACC: Cardio Interv. 2019; DOI: 10.1016/j.jcin.2019.06.046 [Link Here]
25. Lelasi, A., Loffi, M., DeBlasio, G. and Tespili, M. “Rota-tripsy”: a successful combined approach for the treatment of a long heavily calcified coronary lesion. Cardiovascular Revascularization Medicine, [Link Here]

For use outside the U.S. only. Caution: In the United States, Shockwave C2 Coronary IVL catheters are investigational devices, limited by United States law to investigational use. Shockwave C2 Coronary IVL catheters are commercially available in certain countries outside the U.S. Please contact your local Shockwave representative for specific country availability. The Shockwave C2 Coronary IVL catheters are indicated for lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic de novo coronary arteries prior to stenting. Prior to use, please reference the Instructions for Use for more information on indications, contraindications, warnings, precautions and adverse events. Contact Shockwave Medical at customerservice@shockwavelmedical.com

© 2019 Shockwave Medical Inc. All rights reserved. SPL 63409 Rev. B